Please login to the form below

Not currently logged in
Email:
Password:

Merck appoints new senior vice president

Laszlo Radvanyi joinsthe firm
Merck KGgA

Merck KGgA has appointed Laszlo Radvanyi as senior vice president and head of research in immuno-oncology.

Radvanyi will focus on leading the discovery of oncology therapies that leverage the natural ability of the body's immune system to fight cancer, as well as identifying biomarkers with the aim to deliver personalized treatments for patients.

Before joining Merck KGgA, Radvanyi served as chief scientific officer at Lion Biotechnologies based in Florida where he was responsible for developing new technologies to product next-generation TILs for tumor indications including lung, cervical and breast cancer.

Luciano Rossetti, head of global research and development, said: “We are honoured to have Laszio join Merck KGaA. His vast experience across the field of immuno-oncology research is very impressive.

“His expertise and fresh perspective will add significant value to our early-stage immuno-oncology portfolio including combination and biomarker strategies for avelumab and other clinical candidates, as we endeavour to bring new therapeutic options to patients living with cancer.”

4th November 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics